Investment Case

  • Patient-friendly answer to mental health’s unmet needs: Developing two neurological compounds that are desperately needed

  • Potential treatment of COVID-19 variants leading to lower hospitalization and death rate: Novel anti-viral drugs for treatment and potential prevention of pandemics.

  • Management with extensive experience in all aspects of drug development and public company and capital markets management.

  • Several near- and medium-term growth drivers: Growing mental health & COVID-19 markets.

Share Information

STOCK QUOTE: BETR

STOCK QUOTE: BETRF

Analyst Coverage

Andre Uddin, Analyst at Research Capital Corporation

Financial Reports